MVR-C5252
AXP000081.1 · Oncolytic virus
- Platform
- HSV-1 (ICP34.5- ICP47-)
- Originator
- ImmVira Pharma
- Sponsor
- ImmVira Pharma
Names
| Name | Type | Source |
|---|---|---|
| MVR-C5252 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted
- Transgenes
- IL12A, IL12B, anti-PD-1 antibody
- Route
- intracerebral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C184943
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06126744 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 | Recruiting | Phase 1 | 2024-06-11 | 2027-12-01 | 51 | Recurrent High Grade Glioma |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | Unknown | Phase 1 | 2023-03-15 | 2023-04-30 | 51 | Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Notes
Glioma-directed oncolytic HSV-1 carrying IL-12 and an anti-PD-1 antibody; delivered into the brain (NCT06126744). Whether it is the same construct as T3011 with a different delivery device, or a distinct construct, is not fully clear from public sources; entered separately because it has its own NCIt concept and code.
How to cite
MVR-C5252 (AXP000081.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000081.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.